Clinical trial · Observational
Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer
Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer in Head & Neck, Lung, Oesophagus, Anal Canal and Uterine Cervix - a Basis for Personalised Radiotherapy
NCT02379039CI-TRIAL-00072503MORRIScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study's aim is to define imaging and molecular bio-markers for prediction of radiotherapy response of squamous cell carcinomas, in an early treatment phase.
Conditions
Conditions (6)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Cervix Cancer | — | UNRESOLVED | — |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Squamous Carcinoma | Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Loco regional control
- timeFrame
- 2 years
- description
- After completion of radiotherapy
Secondary outcomes (5)
- measure
- Loco regional tumour control (response)
- timeFrame
- 2 months
- description
- After completion of radiotherapy
- measure
- Patterns of failure
- timeFrame
- 2 years
- description
- Time and location of recurrence
- measure
- Overall survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Morphologically (pathology or cytology) verified, previously untreated squamous cell carcinoma (SCC) of the oral cavity, oropharynx, uterine cervix, oesophagus or lung. 2. The patient should be planned for treatment with radiotherapy alone or in combination with concomitant medical therapy 3. The tumour shall be radiologically and/or visually identifiable and accessible for biopsy without the need for general anaesthesia or other major interventions 4. The patient must be at least 18 years of age, able to understand the given information and, leave a written informed consent to participate Exclusion Criteria: 1. The patient is unwilling to participate in the study 2. Patients with adjuvant post-operative radiotherapy (i.e. no visible remaining tumour) 3. Pregnancy or lactation 4. Contraindications to investigations with MRI, gadolinium contrast or PET-tracers 5. Patients with an estimated glomerular filtration rate (GFR) \<60 ml/min/1.73m2. 6. Severe co-morbidities that are judged to significantly compromise survival in a two-years perspective.
References
Publications (1)
- DERIVEDStrandberg S, Jonsson J, Zarei M, Aglund K, Blomqvist L, Soderkvist K. Baseline and early response 2-[18F]FDG-PET/MRI for prediction of radiotherapy outcome in uterine cervical squamous cell carcinoma: a prospective single-center observational cohort study. EJNMMI Rep. 2024 Mar 1;8(1):5. doi: 10.1186/s41824-024-00188-7. PMID 38748271